Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 11400 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - treatment of deep vein thrombosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 15200 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - treatment of deep vein thrombosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 19000 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - treatment of deep vein thrombosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 1900 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 9500 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 7600 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 5700 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 3800 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 2850 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - prophylaxis against deep vein thrombosis (dvt) associated with general or orthopaedic surgery. treatment of dvt. prevention of clotting during haemodialysis. prophylaxis of venous thromboembolism in high-risk medical patients who are immobilised due to acute illness or hospitalised in an intensive care unit.

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - nadroparin calcium - solution for injection in pre-filled syringe - 2,850 i.u. anti-xa/ 0.3 millilitre(s) - heparin group; nadroparin